Reading Time: 2 minutesIntroduction Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a pivotal treatment for type 2 diabetes and obesity. Its efficacy in glycemic control and weight management is well-documented, but the long-term safety profile, particularly in American males, warrants …
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.